(Morning News) Three sources told Reuters that China is actively negotiating with Pfizer's production and distribution permit for the production and distribution of a crown disease.
Sources said that China hopes to strive for the clause to finalize the license before the Lunar New Year, which is used by domestic pharmaceutical vendors to produce and distribute Phaxlovid in China in China.
One of the informed people said that since the end of December 2022, the China Medical Product Supervision Agency, the State Drug Administration, has been leading the negotiations with Pfizer.
The person familiar with the matter said that Beijing hopes to finalize the license clause by January 22.January 22 is the first day of the first month of the Lunar New Year.
Beijing still has a resistance to Western vaccines and treatment to a large extent. Paxlovid is one of the few foreign drugs approved by China's official approval.
A clinical trial shows that PAXLOVID can reduce the hospitalization rate of high -risk patients with crown disease by about 90%.The market's demand for this oral medicine is very large. Many Chinese are trying to buy PAXLOVID from overseas, and then transport them back to China.
